Menu

Theranos in Hot Water with CMS

The blood-testing company must respond to the US Centers for Medicare and Medicaid Services’ allegations of substandard conditions at one of its labs.

Jan 29, 2016
Bob Grant

WIKIMEDIA, VEGASJONUpdate (April 18, 2017): Theranos announced yesterday (April 17) that it had reached a settlement with the Centers for Medicare & Medicaid Services (CMS). This means that the company has resolved all of its outstanding legal and regulatory troubles, that the CMS will not revoke Theranos’s clinical laboratory improvement amendments (CLIA) operating certificates, and that the federal agency has reduced its civil penalty against the firm to $30,000. Theranos “will not own or operate a clinical laboratory within the next two years,” as it had outlined last year, the company said in its statement.

Conditions at one of the laboratories operated by the diagnostics startup Theranos are so bad that, in some respects, they constitute an “immediate jeopardy to patient health and safety,” according to the US government’s Centers for Medicare and Medicaid Services (CMS). The federal agency fired off a letter to Theranos’s lab director Sunil Dhawan earlier this week (January 25), warning that the company had 10 days to address unspecified problems with its blood-based tests, with its analytic systems, and with staff at a facility in Newark, California.

“This type of letter is one step down from ‘we’re shutting you down immediately!’” Tim Hammill, director of clinical labs for the University of California, San Francisco, told Wired. “Then again, any details are completely conjecture because the letter doesn’t say what Theranos is being cited on.”

Theranos is no stranger to running afoul of federal and state regulators. The CMS warned the company in 2013 that 10 of its blood tests failed to meet required standards. In 2014, the California Department of Public Health gave the lab “unsatisfactory” scores on two of its blood tests, according to The Verge.

Theranos told The Verge that the CMS’s inspection began months ago and that the company had since made changes at its Newark lab.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!